138 related articles for article (PubMed ID: 27941526)
1. Epigallocatechin Gallate Extends Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment for Brain Ischemic Stroke: A Randomized Double-Blind and Placebo-Controlled Trial.
Wang XH; You YP
Clin Neuropharmacol; 2017; 40(1):24-28. PubMed ID: 27941526
[TBL] [Abstract][Full Text] [Related]
2. Epigallocatechin Gallate Extends the Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment in Ischemic Rats.
You YP
J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):990-7. PubMed ID: 26851971
[TBL] [Abstract][Full Text] [Related]
3. Fisetin Prolongs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator: A Double-Blind Randomized Placebo-Controlled Clinical Trial.
Wang L; Cao D; Wu H; Jia H; Yang C; Zhang L
Clin Appl Thromb Hemost; 2019; 25():1076029619871359. PubMed ID: 31434498
[TBL] [Abstract][Full Text] [Related]
4. Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial.
Schellinger PD; Alexandrov AV; Barreto AD; Demchuk AM; Tsivgoulis G; Kohrmann M; Alleman J; Howard V; Howard G; Alexandrov AW; Brandt G; Molina CA;
Int J Stroke; 2015 Oct; 10(7):1141-8. PubMed ID: 26120902
[TBL] [Abstract][Full Text] [Related]
5. Ginsenoside Represses Symptomatic Intracerebral Hemorrhage after Recombinant Tissue Plasminogen Activator Therapy by Promoting Transforming Growth Factor-β1.
Chen J; Bai Q; Zhao Z; Sui H; Xie X
J Stroke Cerebrovasc Dis; 2016 Mar; 25(3):549-55. PubMed ID: 26683593
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol improves delayed r-tPA treatment outcome by reducing MMPs.
Chen J; Bai Q; Zhao Z; Sui H; Xie X
Acta Neurol Scand; 2016 Jul; 134(1):54-60. PubMed ID: 26455907
[TBL] [Abstract][Full Text] [Related]
7. Simple clinical predictors of stroke outcome based on National Institutes of Health Stroke scale score during 1-h recombinant tissue-type plasminogen activator infusion.
Osaki M; Miyashita F; Koga M; Fukuda M; Shigehatake Y; Nagatsuka K; Minematsu K; Toyoda K
Eur J Neurol; 2014 Mar; 21(3):411-8. PubMed ID: 24200315
[TBL] [Abstract][Full Text] [Related]
8. Intravenous thrombolysis for acute ischemic stroke in the 3- to 4·5-hour window--the Malabar experience.
Salam KA; Ummer K; Pradeep Kumar VG; Noone ML
Int J Stroke; 2014 Jun; 9(4):426-8. PubMed ID: 23981667
[TBL] [Abstract][Full Text] [Related]
9. Sodium Tanshinone IIA Sulfonate Enhances Effectiveness Rt-PA Treatment in Acute Ischemic Stroke Patients Associated with Ameliorating Blood-Brain Barrier Damage.
Ji B; Zhou F; Han L; Yang J; Fan H; Li S; Li J; Zhang X; Wang X; Chen X; Xu Y
Transl Stroke Res; 2017 Aug; 8(4):334-340. PubMed ID: 28243834
[TBL] [Abstract][Full Text] [Related]
10. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke.
Lang W; Stadler CH; Poljakovic Z; Fleet D;
Int J Stroke; 2013 Feb; 8(2):95-104. PubMed ID: 23009193
[TBL] [Abstract][Full Text] [Related]
11. Tissue plasminogen activator (rt-PA) in acute ischemic stroke: Outcomes associated with ambulation.
Lawson TR; Brown IE; Westerkam DL; Blackhurst DW; Sternberg S; Leacock R; Nathaniel TI
Restor Neurol Neurosci; 2015; 33(3):301-8. PubMed ID: 25698111
[TBL] [Abstract][Full Text] [Related]
12. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
[TBL] [Abstract][Full Text] [Related]
13. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator?
Hassan AE; Zacharatos H; Hassanzadeh B; El-Gengaihy A; AlKawi A; Shhadeh A; Kirmani JF
J Stroke Cerebrovasc Dis; 2010 Mar; 19(2):116-20. PubMed ID: 20189087
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of the Cincinnati Prehospital Stroke Scale for identifying thrombolytic candidates in acute ischemic stroke.
You JS; Chung SP; Chung HS; Lee HS; Park JW; Kim HJ; Lee SH; Park I; Lee HS
Am J Emerg Med; 2013 Dec; 31(12):1699-702. PubMed ID: 24055479
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke.
Amaro S; Soy D; Obach V; Cervera A; Planas AM; Chamorro A
Stroke; 2007 Jul; 38(7):2173-5. PubMed ID: 17525395
[TBL] [Abstract][Full Text] [Related]
16. Baseline National Institutes of Health stroke scale-adjusted time window for intravenous tissue-type plasminogen activator in acute ischemic stroke.
Muchada M; Rubiera M; Rodriguez-Luna D; Pagola J; Flores A; Kallas J; Sanjuan E; Meler P; Alvarez-Sabin J; Ribo M; Molina CA
Stroke; 2014 Apr; 45(4):1059-63. PubMed ID: 24603070
[TBL] [Abstract][Full Text] [Related]
17. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.
Adeoye O; Sucharew H; Khoury J; Tomsick T; Khatri P; Palesch Y; Schmit PA; Pancioli AM; Broderick JP;
Stroke; 2015 Feb; 46(2):461-4. PubMed ID: 25523054
[TBL] [Abstract][Full Text] [Related]
18. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
Kwiatkowski TG; Libman RB; Frankel M; Tilley BC; Morgenstern LB; Lu M; Broderick JP; Lewandowski CA; Marler JR; Levine SR; Brott T
N Engl J Med; 1999 Jun; 340(23):1781-7. PubMed ID: 10362821
[TBL] [Abstract][Full Text] [Related]
19. The correlation between admission blood glucose and intravenous rt-PA-induced arterial recanalization in acute ischemic stroke: a multi-centre TCD study.
Saqqur M; Shuaib A; Alexandrov AV; Sebastian J; Khan K; Uchino K
Int J Stroke; 2015 Oct; 10(7):1087-92. PubMed ID: 26332252
[TBL] [Abstract][Full Text] [Related]
20. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
Bluhmki E; Chamorro A; Dávalos A; Machnig T; Sauce C; Wahlgren N; Wardlaw J; Hacke W
Lancet Neurol; 2009 Dec; 8(12):1095-102. PubMed ID: 19850525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
